Tech Company Financing Transactions

Corvus Pharmaceuticals Funding Round

Rock Springs Capital, Adams Street Partners and BlackRock joined a $75 million Series B funding round for Corvus Pharmaceuticals. The round was announced on 9/30/2015.

Transaction Overview

Company Name
Corvus Pharmaceuticals
Announced On
9/30/2015
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Series B
Investors

Rock Springs Capital (Lead Investor)

Adams Street Partners (Terry Gould)

BlackRock

Cormorant Asset Management

Cowen Capital Partners

Fidelity Management & Research Company

Novo Ventures (Peter Moldt)

OrbiMed (Peter Thompson)

Roche Venture Fund

venBio

Proceeds Purpose
The proceeds will be used to expand the company's research and development programs of multiple small molecule and antibody agents in immuno-oncology, including the initiation of a multicenter Phase 1B trial, which is expected to begin in the first quarter of 2016.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
863 Mitten Rd. 102
Burlingame, CA 94010
USA
Phone
(650) 900-4520
Website
www.corvuspharma.com
Email Address
Not Recorded
Overview
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer.
Profile
Corvus Pharmaceuticals LinkedIn Company Profile
Social Media
Corvus Pharmaceuticals Company Twitter Account
Company News
Corvus Pharmaceuticals News
Facebook
Corvus Pharmaceuticals on Facebook
YouTube
Corvus Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Richard Miller
  Richard Miller LinkedIn Profile  Richard Miller Twitter Account  Richard Miller News  Richard Miller on Facebook
Chief Financial Officer
Leiv Lea
  Leiv Lea LinkedIn Profile  Leiv Lea Twitter Account  Leiv Lea News  Leiv Lea on Facebook
Vice President
Long Kwei
  Long Kwei LinkedIn Profile  Long Kwei Twitter Account  Long Kwei News  Long Kwei on Facebook
VP - Bus. Development
Daniel Hunt
  Daniel Hunt LinkedIn Profile  Daniel Hunt Twitter Account  Daniel Hunt News  Daniel Hunt on Facebook
VP - Bus. Development
William Jones
  William Jones LinkedIn Profile  William Jones Twitter Account  William Jones News  William Jones on Facebook
VP - R & D
Joseph Buggy
  Joseph Buggy LinkedIn Profile  Joseph Buggy Twitter Account  Joseph Buggy News  Joseph Buggy on Facebook
VP - R & D
Erik Verner
  Erik Verner LinkedIn Profile  Erik Verner Twitter Account  Erik Verner News  Erik Verner on Facebook

 

 

Browse more venture capital transactions:

Prev: 9/30/2015: Bionova Medical venture capital transaction
Next: 9/30/2015: Norse venture capital transaction

 

Share this article

 

About Our VC Transactions Data

Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.